When NAbs titers measured by neutralization assays are correlated with the severity of SARS-CoV-2 infection, it has been established that patients who had severe infections had a stronger NAbs response and the NAbs lasted longer. By comparison, asymptomatic patients have low levels of specific IgG, long persistence of viral RNA, and did not display a strong antibody response. Therefore, asymptomatic patients may have a risk of breakthrough infection.
